{'fraction_non_alphanumeric': 0.024933214603739984, 'fraction_numerical': 0.014247551202137132, 'mean_word_length': 5.14207650273224, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Ketanserin and the cardiovascular response to intubation: a preliminary report.

Several methods of attenuating the adverse cardiovascular effects of laryngoscopy and intubation are available. The obtunding effect of ketanserin 0.5 mg kg-1 versus that of a placebo, given 5 min prior to intubation, was investigated in a randomized double-blind trial in a group of 40 patients. Blood pressure (systolic, mean and diastolic) and pulse rate were measured at 1-min intervals with an Accutor blood pressure apparatus for 5 min before and 5 min after the injection of ketanserin or placebo, as well as for 6 min after a standardized induction (thiopentone and suxamethonium), laryngoscopy and intubation. The patients who had received ketanserin had a statistically significant lower systolic blood pressure (1 and 4 min), as well as significantly lower mean and diastolic blood pressures at 1, 2, 3 and 4 min. There were no unexpected untoward side-effects. Further investigations are suggested using ketanserin as part of a multi-faceted pharmacological approach to decrease the adverse effects of laryngoscopy and intubation.